Biostem Technologies (BSEM) Expected to Post Earnings on Thursday

Biostem Technologies (NASDAQ:BSEM) is projected to issue its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect Biostem Technologies to post earnings of ($0.43) per share and revenue of $7.17 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:30 PM ET.

Biostem Technologies (NASDAQ:BSEM) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.02). The business had revenue of $7.90 million during the quarter, compared to analysts’ expectations of $6.35 million. Biostem Technologies had a negative return on equity of 60.22% and a negative net margin of 76.02%. On average, analysts expect Biostem Technologies to post ($1.90) EPS for the current fiscal year and ($1.04) EPS for the next fiscal year.

Biostem Technologies Price Performance

NASDAQ:BSEM opened at $1.15 on Thursday. The business’s 50-day simple moving average is $2.93 and its two-hundred day simple moving average is $4.15. The stock has a market cap of $21.47 million, a PE ratio of -0.72 and a beta of 0.36. Biostem Technologies has a 52 week low of $1.04 and a 52 week high of $8.40.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Wall Street Zen raised Biostem Technologies to a “sell” rating in a research note on Saturday, September 5th. Weiss Ratings assumed coverage on Biostem Technologies in a research report on Wednesday, August 19th. They set a “sell (d-)” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $9.00.

Biostem Technologies Company Profile

BioStem Technologies, Inc is a biotechnology company focused on regenerative medicine and biologic tissue products. The company develops, manufactures and commercializes human tissue allografts intended to support wound care, tissue repair and other medical applications.

Its product portfolio includes placental- and birth-tissue-derived products, such as amniotic membrane and umbilical cord allografts. These products are marketed for use by healthcare providers in areas including wound management, surgical procedures and related regenerative-care applications.

BioStem Technologies serves the U.S.